clinical trial · NCT07101705
An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology·early phase1·recruiting·n = 40
Multiple Myeloma (MM)Non-Hodgkin Lymphoma (NHL)OriV508 Injection
brief summary
This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability, preliminary efficacy and immunogenicity of OriV508 injection for patients with relapsed/refractory hematological malignancies.
started
Sep 8, 2025
primary completion
Aug 1, 2028
completion
Aug 1, 2028
last updated
Sep 9, 2025
detailed description
This investigator-initiated clinical study aims to evaluate OriV506 injection, the self-inactivating lentiviral vector that carries a BCMA/CD19 dual-target CAR, in patients with relapsed refractory B-cell hematological malignancies. The study employs a dose-escalation design to assess safety, tolerability, and preliminary efficacy.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol